Well over half of all COVID-19 patients experience neurological symptoms during the acute phase of the infection. Whilst most of these symptoms disappear after the infection, some may persist after recovery or even emerge for the first time weeks later. These include neurological, neuropsychological and neuropsychiatric symptoms such as cognitive impairment, sleep disturbances, headaches, dizziness, depression, anxiety, gait disturbances and general fatigue. The aetiology of these symptoms remains unclear, which is why effective treatments are still lacking.
Researchers at the Institute of Pharmacology, Toxicology and Pharmacy at the Hannover Veterinary University Foundation (TiHo) have now published research findings that shed light on how a SARS-CoV-2 infection alters the protein structure of nerve cells in the brain and could thereby lead to post-COVID symptoms.
The research team examined the brains of Syrian golden hamsters infected with SARS-CoV-2, both during and after the infection. To do this, brain sections were prepared and detailed analyses carried out. “For the acute phase of infection, we were able to show that SARS-CoV-2 activates immune defence cells in the epithelium of the nasal cavity and in the olfactory bulb of the brain,” reports lead researcher Franziska Richter Assencio: “Notably, there was strong activation of microglial cells in the brain tissue – that is, the local immune defence – which was still present 14 days after infection.”
Following infection, the researchers found clusters of proteins prone to misfolding and structural changes (alpha-synuclein and tau proteins) – similar to those seen in patients with Alzheimer’s and Parkinson’s disease – accumulating in the nerve cells of the cerebral cortex. These accumulations could lead to disorders of the nervous system and, for example, explain the concentration and memory problems reported by many people with Long COVID. “The fact that not all regions of the brain were affected is an important finding. This points to a selective susceptibility, as is characteristic of neurodegenerative diseases,” explains Richter Assencio.
Further studies are now needed to clarify whether the accumulation of tau and alpha-synuclein is the cause of the long-lasting neurological symptoms. They must also determine whether, based on these findings, a treatment for the symptoms of Long Covid can be developed.
Reference:
Hannover
University of Veterinary Medicine Foundation. Microgliosis and neuronal proteinopathy in the brain persist beyond viral clearance in a SARS-CoV-2 hamster model, eBioMedicine 2022; https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(22)00183-9/fulltext